SCHEMBL112918

SCHEMBL112918

O=C1OC2(c3ccccc31)c1ccc(O)c(I)c1Oc1c2ccc(O)c1I

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNG2 P59768 1/20 0.74
GNB1 P62873 1/20 0.74
MEN1 O00255 5/20 0.67
KMT2A Q03164 5/20 0.67
TDP1 Q9NUW8 4/20 0.67
RECQL P46063 2/20 0.67
BLM P54132 2/20 0.67
ACE2 Q9BYF1 2/20 0.67
L3MBTL1 Q9Y468 2/20 0.67
USP2 O75604 2/20 0.67
THRB P10828 1/20 0.67
CDK2 P24941 1/20 0.67
CHAT P28329 1/20 0.67
BLVRB P30043 1/20 0.67
RXFP1 Q9HBX9 1/20 0.67
MAPT P10636 6/20 0.55
PRMT1 Q99873 2/20 0.55
FTO Q9C0B1 2/20 0.55
CYP2C19 P33261 2/20 0.55
HTT P42858 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29379080 1.00 GNG2 (0.74) GNG2GNB1MEN1KMT2ATDP1
SCHEMBL3182620 0.99 GNG2 (0.72) GNG2GNB1MEN1KMT2ATDP1
SCHEMBL3182615 0.99 GNG2 (0.72) GNG2GNB1MEN1KMT2ATDP1
SCHEMBL30160637 0.90 MEN1 (0.86) GNG2GNB1MEN1KMT2ATDP1
SCHEMBL3625922 0.90 MEN1 (0.86) GNG2GNB1MEN1KMT2ATDP1
SCHEMBL20907331 0.88 FTO (0.73) GNG2GNB1MEN1KMT2ATDP1
SCHEMBL5364186 0.87 MEN1 (0.62) GNG2GNB1MEN1KMT2ATDP1
SCHEMBL30408346 0.85 GNG2 (1.00) GNG2GNB1MEN1KMT2ATDP1
SCHEMBL29942282 0.85 GNG2 (1.00) GNG2GNB1MEN1KMT2ATDP1
SCHEMBL29424349 0.85 GNG2 (1.00) GNG2GNB1MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
US-20230310285-A1 DEVELOPER COMPOSITION COMPRISING DIRECT DYE L'OREAL (FR) 2023-10-05 US claimed
WO-2023192788-A1 DEVELOPER COMPOSITION COMPRISING DIRECT DYE L'OREAL (FR) 2023-10-05 WO claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
US-7842826-B2 Process for synthesizing halogenated derivatives of fluorescein for use in the production of non-volatile memory devices STMICROELECTRONICS S.R.L. (IT) 2010-11-30 US claimed
US-20080061289-A1 PROCESS FOR SYNTHESIZING HALOGENATED DERIVATIVES OF FLUORESCEIN FOR USE IN THE PRODUCTION OF NON-VOLATILE MEMORY DEVICES STMICROELECTRONICS S.R.L. (IT) 2008-03-13 US claimed
US-20030108488-A1 Compositions and methods to inhibit tartar and microbes using denture adhesive compositions with colorants PROCTER & GAMBLE COMPANY, THE 2003-06-12 US claimed
US-20260048025-A1 COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES NATURAL EXTRACTION SYS LLC (US) 2026-02-19 US disclosed
US-12496344-B2 Biophotonic materials and uses thereof FLE INT S R L (IT) 2025-12-16 US disclosed
US-12377068-B2 In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors PROVECTUS PHARMATECH, INC. (US) 2025-08-05 US disclosed
US-12281180-B2 Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same NEW YORK UNIVERSITY (US) 2025-04-22 US disclosed
US-20250108658-A1 INKJET PRINTING PROCESSES FOR TEMPORARY TATTOOS Prism Inks, Inc. (US) 2025-04-03 US disclosed
US-12133840-B2 Halogenated xanthene composition and method for treating hematologic cancers PROVECTUS PHARMATECH, INC. (US) 2024-11-05 US disclosed
EP-0261934-A2 Rapid differentiation of bacteria using cyclic polypeptide antibiotics EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1988-03-30 EP disclosed
EP-0261933-A2 Rapid differentiation of bacteria using polyether antibiotics EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1988-03-30 EP disclosed
EP-0259133-A2 Use of organic buffers to reduce dehydroascorbic acid interference in analytical methods EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1988-03-09 EP disclosed
EP-0247848-A2 Water-compatible reducible compounds and their use in analytical compositions and methods EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1987-12-02 EP disclosed
EP-0211898-A1 REDUCIBLE COMPOUNDS AND ANALYTICAL COMPOSITIONS, ELEMENTS AND ME THODS UTILIZING SAME. EASTMAN KODAK CO (US) 1987-03-04 EP disclosed
WO-1986004681-A1 REDUCIBLE COMPOUNDS AND ANALYTICAL COMPOSITIONS, ELEMENTS AND ME THODS UTILIZING SAME EASTMAN KODAK COMPANY (US) 1986-08-14 WO disclosed
EP-0190740-A2 Use of substituted quinone electron transfer agents in analytical determinations EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1986-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080061289-A1 PROCESS FOR SYNTHESIZING HALOGENATED DERIVATIVES OF FLUORESCEIN FOR USE IN THE PRODUCTION OF NON-VOLATILE MEMORY DEVICES FASTKD5, KCNA5, KCNQ5 GNG2 3802/4885GNB1 3231/4885MEN1 2830/4885
US-12377068-B2 In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors RNASE1, XDH, TYR GNG2 2633/4885GNB1 1488/4885MEN1 740/4885
US-12133840-B2 Halogenated xanthene composition and method for treating hematologic cancers ETV6, BCL6, XPA GNG2 1002/4885GNB1 694/4885MEN1 473/4885
US-20030108488-A1 Compositions and methods to inhibit tartar and microbes using denture adhesive compositions with colorants TAS2R10, TAS1R1, TAS2R40 GNG2 2360/4885GNB1 2782/4885MEN1 4820/4885
US-20230310285-A1 DEVELOPER COMPOSITION COMPRISING DIRECT DYE TYR, CYB5R3, POLR1C GNG2 1706/4885GNB1 2112/4885MEN1 2132/4885
US-20260048025-A1 COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES SCO2, CNR2, CNR1 GNG2 1435/4885GNB1 801/4885MEN1 1906/4885
US-12281180-B2 Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same WNT1, WNT3, WNT3A GNG2 804/4885GNB1 948/4885MEN1 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.